Mark P Carthy

Previously, he served as a General Partner at Oxford Bioscience Partners. He joined the firm in October 2000 and was based at the firm’s office in Boston. He has more than 20 years of experience operating or investing in high technology companies. Previously, Mr. Carthy was Biotechnology Portfolio Manager at Morningside Ventures where he focused on early stage private equity investments. From 1998 to ... 2000, Mr. Carthy was an Advisor to Kummell Investments Limited. Previously, he was the Chief Business Officer of Cubist Pharmaceuticals, Inc. and was responsible for finance, business development, and business operations. Mr. Carthy also served as a Senior Director of Business Development at Vertex Pharmaceuticals Incorporated. He currently serves as a Director of Astex Technology, ImpactRx, Scion Pharmaceuticals, Xanathus Life Sciences, Lynx Therapeutics Inc., Ensemble Discovery Corp., Affinium Pharmaceuticals, Inc., and Cyberkinetics. Mr. Carthy has been a Chairman and Director of Cyberkinetics Neurotechnology Systems Inc. since August 2002. He had served as a Director of Solexa since 2001. Mr. Carthy served as a Director of Variagenics and Dendreon. Mr. Carthy holds a B.E. in Chemical Engineering from University College Dublin, Ireland, an M.S. in Chemical Engineering from University of Missouri, and an M.B.A. from Harvard Business School.